JY
ATXI

Jeff Yass’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Jeff Yass’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-959
Closed -$10.6K – 13444
2024
Q1 		$10.6K Buy
+959
New +$11.4K ﹤0.01% 11901
2022
Q3 		– Sell
-23
Closed -$7K – 14305
2022
Q2 		$7K Buy
+23
New +$8.86K ﹤0.01% 12577
2020
Q2 		– Sell
-18
Closed -$181K – 11103
2020
Q1 		$181K Buy
+18
New +$180K ﹤0.01% 8804

Other funds holding ATXI

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jeff Yass's ATXI Position: Q2 2024 in Review

Jeff Yass sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q2 2024, closing a stake of 959 shares — an estimated $10.6K sold.

Jeff Yass first reported a position in ATXI in Q1 2020 and held it in 3 quarters. The position peaked at $181K in Q1 2020. 9 funds tracked by Wall St. Rank hold ATXI as of Q2 2024.

  • Jeff Yass reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Jeff Yass sold 959 Avenue Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $10.6K.
  • Jeff Yass first reported a position in Avenue Therapeutics, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Jeff Yass's Avenue Therapeutics, Inc. Common Stock position peaked at $181K in Q1 2020.
  • 9 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.